Risk factors for progression in disease extent within 10 years*
| Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex (male) | 0.90 (0.41 to 1.94) | 0.78 | 0.81 (0.35 to 1.88) | 0.63 |
| Age at baseline | ||||
| Paediatric (<18 years) | 4.86 (1.89 to 12.48) | <0.01 | 4.50 (1.55 to 13.08) | <0.01 |
| Adult (19–49 years) | Reference | Reference | ||
| Elderly (>50 years) | 0.52 (0.15 to 1.76) | 0.29 | 0.38 (0.11 to 1.36) | 0.14 |
| Disease extent | ||||
| E1, proctitis | 2.20 (0.75 to 6.39) | 0.15 | 1.08 (0.33 to 3.57) | 0–90 |
| E2, left-sided colitis | Reference | Reference | ||
| Previous medical therapy† | ||||
| 5-Aminosalicylates | Reference | Reference | ||
| Corticosteroids | 2.15 (0.29 to 15.87) | 0.45 | 1.66 (0.23 to 12.67) | 0.63 |
| Year of thiopurine initiation‡ | 1.13 (0.82 to 1.56) | 0.46 | 1.15 (0.80 to 1.67) | 0.45 |
| Thiopurine tolerance | 0.45 (0.21 to 0.97) | 0.04 | 0.47 (0.21 to 1.06) | 0.07 |
| Admitted to hospital at diagnosis | 1.37 (0.47 to 3.98) | 0.56 | 1.16 (0.36 to 3.74) | 0.80 |
*Only patients with proctitis or left-sided colitis at start of the first thiopurine drug were included (thiopurine tolerant, n=67; intolerant, n=35).
†All patients had received some kind of treatments at baseline while none of the patients were exposed to anti-tumour necrosis factor agents.
‡The time of thiopurine initiation was categorised in 5-year intervals: 1981–1985; 1986–1990; 1991–1995; 1996–2000; 2001–2005; 2006–2010; 2011–2015.